1. TM6SF2: A novel target for plasma lipid regulation
- Author
-
Zhi-Han Tang, Xi-Long Zheng, Zhi-Sheng Jiang, Bei He, Tao-Hua Li, Lu-Shan Liu, Dang-Heng Wei, Juan Peng, and Ting-Ting Li
- Subjects
0301 basic medicine ,Regulator ,Mice, Transgenic ,Intestinal absorption ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,medicine ,Animals ,Humans ,Dyslipidemias ,Gene knockdown ,Cholesterol ,Anticholesteremic Agents ,Fatty liver ,Membrane Proteins ,Lipid metabolism ,medicine.disease ,Cell biology ,030104 developmental biology ,chemistry ,Intestinal Absorption ,Liver ,Intestinal cholesterol absorption ,lipids (amino acids, peptides, and proteins) ,030211 gastroenterology & hepatology ,Cardiology and Cardiovascular Medicine ,Biomarkers ,TM6SF2 - Abstract
Transmembrane 6 superfamily 2 (TM6SF2), a gene identified at the locus 19p12, has been recognized to regulate plasma lipids. Here, we provide an overview of the roles of TM6SF2 as a novel target for plasma lipid regulation. We first review the association of TM6SF2 variant with plasma lipid traits, cardiovascular disease (CVD) and non-alcoholic fatty liver disease (NAFLD). Then, we present an overview about the in vivo validation of TM6SF2 as a regulator of plasma lipid levels using mice, with overexpression or knockdown/knockout of TM6SF2. Thereafter, we discuss the mechanisms underlying TM6SF2 regulation of lipid metabolism involving intestinal cholesterol absorption and hepatic cholesterol biosynthesis and transport. In conclusion, increasing evidence suggests that TM6SF2 may be a major regulator of plasma lipid levels and become a therapeutic target in cardiovascular disease.
- Published
- 2017